Fate Therapeutics Inc is a clinical-stage biopharmaceutical company which develops programmed cellular immunotherapies for cancer and immune disorders. It uses pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of cells ex vivo before the product candidates are administered to a patient. In other cases, it uses human induced pluripotent stem cells (iPSCs), generates a master iPSC line having preferred biological properties, and direct the fate of the iPSC line to create a clonal population.